Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus apatinib for perioperative treatment of resectable oral cancer
ChiCTR2100051989Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab and Rivoceranib in mouth cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: major pathological remission. Planned start Nov 2021; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
mouth cancer
Beyond the preview
Go deeper on ChiCTR2100051989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051989.